Analysts have identified their top technology stock picks, including InSilico Medicine Cayman TopCo (HK:3696) and Semiconductor Manufacturing International (HK:0981).

Insilico Medicine and SK Biopharmaceuticals have announced a $2.5 billion deal focused on AI drug discovery, specifically targeting neuroimmune therapies.

Insilico Medicine has partnered with a US firm to develop an artificial intelligence model aimed at advancing research into human longevity.

Hong Kong-listed Insilico Medicine has signed a cooperation agreement with the United Arab Emirates' drug regulator to advance the use of its AI tools in drug discovery across the region.

Insilico Medicine has demonstrated that generative AI can significantly accelerate drug discovery, but the company's larger challenge lies in transforming this breakthrough into a repeatable and consistent process.

Insilico Medicine has partnered with SK Biopharmaceuticals in a significant $2.5 billion agreement focused on AI-driven drug discovery.

Eli Lilly is deepening its commitment to artificial intelligence in drug discovery by expanding its existing partnership with Insilico Medicine.

Takeda has made a new investment in AI-driven drug discovery by partnering with Insilico Medicine, aiming to leverage artificial intelligence for pharmaceutical innovation.

Hong Kong-listed AI drug-discovery company Insilico Medicine has announced a collaboration with US-headquartered Human Longevity to co-develop large-scale AI foundation models aimed at predicting diseases decades in advance.